News Quantified

ADPT – adaptive biotechnologies corporation (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026 [Yahoo! Finance]

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies (NASDAQ:ADPT) had its "buy" rating reaffirmed by analysts at Cowen Inc.

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle [Seeking Alpha]

-11.5%

BEAT

5.8%

BEAT

33.7%

BEAT

-0.9%

BEAT

Form 4 Adaptive Biotechnologies For: Jan 12 Filed by: LO FRANCIS

Form 4 Adaptive Biotechnologies For: Jan 12 Filed by: PISKEL KYLE

Form 144 Adaptive Biotechnologies Filed by: LO FRANCIS

Form 144 Adaptive Biotechnologies Filed by: PISKEL KYLE

Form 8-K Adaptive Biotechnologies For: Jan 12

Top News Gainers

6/27 Form 424B4 Adaptive Biotechnologies 17.2%

1/23 Adaptive Announces Pricing of Public Offering of Common Stock 13.8%

8/13 Adaptive Biotechnologies stock tumbles after first earnings report since IPO [CNBC] 12.2%

12/4 Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients 8.7%

4/18 Adaptive Biotechnologies Corporation (NASDAQ: ADPT) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $46.00 price target on the stock. 7.4%

11/1 Illumina's Next Big Move: Distributed Diagnostics [The Motley Fool] 6.8%

6/27 Adaptive Biotech and BridgeBio shares rocket higher on their first day of trade [MarketWatch] 6.3%

8/7 Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle’s Growing Biotech Hub 5.7%

11/15 Adaptive Biotechnologies Corporation (NASDAQ: ADPT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $36.00 price target on the stock. 5.4%

1/7 Form 4 Adaptive Biotechnologies For: Jan 06 Filed by: HILL NANCY LOUISE 5.3%

Top News Decliners

3/11 Form 4 Adaptive Biotechnologies For: Mar 09 Filed by: Cohen Chad M -17.8%

11/12 Form 10-Q Adaptive Biotechnologies For: Sep 30 -11.7%

4/2 Adaptive Biotechnologies Corporation (NASDAQ: ADPT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -9.8%

1/15 Adaptive Biotechnologies (ADPT) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] -8.3%

2/26 Form 8-K Adaptive Biotechnologies For: Feb 26 -7.8%

9/23 Adaptive Biotechnologies Corporation (NASDAQ: ADPT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $45.00 price target on the stock. -7.1%

9/24 Form 8-K Adaptive Biotechnologies For: Sep 24 -6.4%

4/22 Form 4 Adaptive Biotechnologies For: Apr 20 Filed by: ROBINS HARLAN S -5.9%

8/2 Form 8-K Adaptive Biotechnologies For: Jul 31 -5.9%

1/17 Form 4 Adaptive Biotechnologies For: Jan 15 Filed by: ROBINS HARLAN S -4.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day